Hunan Warrant Pharmaceutical (SHA:688799) received approval from China's drug administrator for the listing application of its active pharmaceutical ingredient bismuth potassium citrate.
Bismuth potassium citrate is a gastric mucosal protective agent, commonly used to treat chronic gastritis and alleviate acid-related stomach pain, according to a Monday filing with the Shanghai bourse.
Shares of the pharmaceutical company closed 4% higher Monday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。